Oil USO 0.00%↑ just ripped 11% in a single day and hit extreme-high RSI levels.
Everyone’s chasing the commodity run.
I’m doing the opposite.
While the crowd piles into overextended energy plays, I’m hunting for quality names trading at deep discounts.
Names that have been beaten down during the rotation, but are positioned at the forefront of a medical revolution.
What I’m Watching This Week
I’m laser-focused on a gene editing pioneer that’s already brought the world’s first CRISPR-based therapy to market.
This company is using breakthrough technology to cure, not just treat, genetically defined diseases like sickle-cell disease, beta-thalassemia, and potentially Type 1 diabetes.
The stock is trading 54% below its fair value and sitting in an accumulation zone below its 200-day SMA.
This is a world-class biotech company on sale while the market chases shiny objects.
This setup works for both traders and investors:
Buy-and-hold investors: Accumulate shares in a gene editing leader at a massive discount.
Swing traders: Clean technical setup with defined risk and 50%+ upside to previous highs.
I’ve also lined up two backup picks!!
A small-cap mean reversion play and a defensive sector rotation that’s benefiting from the Bonds (TLT) breakout. Both offer 3x leveraged options for aggressive traders.
Here’s what you’ll get in today’s full breakdown:
✅ Complete fundamental analysis on this week’s top pick; the gene editing company that brought the first CRISPR therapy to market, their pipeline, and why they’re a key player in the future of medicine.
✅ Technical setup with specific price levels: entry zones, stop loss, and three profit targets (including fair value at $106).
✅ Position sizing strategy for both buy-and-hold and swing trades.
✅ 2 backup picks with full entry/exit plans.
✅ The teaching moment: How I found value in beaten-down sectors while everyone else chases overextended plays.
This is the same systematic approach I use in my Sunday Market Playbook—applied to actionable trade ideas you can execute this week.
Ready to see the full analysis? LFG!!
Nurse in The Market’s TOP PICK OF THE WEEK: Thursday, April 2, 2026!
CRISPR Therapeutics AG (CRSP)
Current Price: $49.51
Sector: Health Care XLV 0.00%↑
Sub-sector: Biotechnology
Market Cap: $4.2B
Fair Value: $106 (54% discount to fair value)
Market Context
The market is rotating hard into commodities and defensive assets.
Oil USO 0.00%↑ surged 11.15% today with an extreme-high RSI reading; a classic overextension.
Bonds TLT 0.00%↑ and the Dow Jones DIA 0.00%↑ broke above their 20-day SMAs and 200-day SMAs, leading the charge!
Meanwhile, the S&P 500 SPY 0.00%↑ and Nasdaq QQQ 0.00%↑ remain stuck in accumulation zones below their 200-day SMAs.
Bitcoin ($BTCUSD) sits at the bottom of the Market Vitals as the worst performer.
The message: rotation out of growth/tech and into commodities and defensives.
The opportunity: Quality biotech names got crushed in this rotation and are now trading at massive discounts.
While everyone chases oil (USO), smart money is quietly accumulating beaten-down healthcare stocks (XLV) positioned at the forefront of revolutionary medical breakthroughs.
Fundamental Analysis
Who CRSP Is
CRISPR Therapeutics AG CRSP 0.00%↑ is a gene editing company using CRISPR/Cas9 technology to treat genetically defined diseases.
Think of it like molecular scissors that precisely cut and edit DNA.
The company brought the world’s first CRISPR-based therapy to market: Casgevy (developed with Vertex Pharmaceuticals).
Casgevy treats sickle-cell disease and beta-thalassemia, life-threatening blood disorders with high unmet medical needs.
This is a functional cure, not just symptom management.
Beyond Casgevy, CRSP is advancing programs in:
Immuno-oncology (cancer treatments).
Cardiovascular diseases.
Type 1 diabetes (stem cell therapy to restore insulin production).
Why Invest in CRSP Right Now
First-Mover Advantage: CRSP is the only gene editing company with an approved commercial product.
Casgevy’s approval proves CRISPR works in humans and can pass regulatory scrutiny.
Massive Market Opportunity: Gene editing is projected to reach tens of billions of dollars over the next decade, with applications across oncology, rare diseases, cardiovascular, and metabolic disorders.
Strong Partnership: The Vertex collaboration validates CRSP’s platform and provides commercial expertise and capital to scale Casgevy globally.
Deep Pipeline: Multiple shots on goal across immunooncology, cardiovascular, and diabetes—each a potential blockbuster.
Trading at a Massive Discount: At $49.51, CRSP is 54% below fair value of $106.
The market rotation created a rare accumulation opportunity.
Key Player Status
CRISPR Therapeutics CRSP 0.00%↑ is one of the top three gene editing companies globally (alongside Editas and Intellia), but it’s the only one with an approved commercial product.
This Gives CRSP:
Proof of concept.
Regulatory expertise.
Real-world traction.
The company is a category-defining pioneer in one of the most transformative technologies in modern medicine.
CRSP also leverages AI to predict off-target DNA edits, identify disease targets, and optimize delivery mechanisms.
Gene editing can cure previously untreatable diseases and CRSP is at the forefront!!
Interesting, Lesser-Known Facts About CRSP
Casgevy Is a One-Time Functional Cure: Administered once for a lifetime cure of sickle-cell disease and beta-thalassemia!!
This is a paradigm shift from lifelong daily medication!!
Nobel Prize Connection: CRSP won the Nobel Prize in Chemistry in 2020!!
CRSP is translating Nobel-winning science into real therapies.
The Thesis FOR CRSP
Why This Stock, Right Now
53% Discount to Fair Value: CRSP at $49.51 vs. fair value of $106. The rotation punished biotech creating opportunity.
First Approved CRISPR Therapy: Casgevy proves the platform works, de-risking future pipeline programs.
Multiple Catalysts Ahead: Clinical readouts for immunooncology, cardiovascular, and diabetes programs over the next 12-24 months.
Contrarian Play: Everyone’s chasing oil at extreme-high RSI readings.
You’re positioning in a beaten-down gene editing leader.
Risk/Reward: Risk $6 to target $60-62, $74-78, or $106. That’s 2:1 to 10:1 reward/risk.
CRSP Technical Setup & Chart Markup &Analysis
CRSP is in an accumulation zone below its 200-day SMA after selling off from $78 highs to $49.
The stock has also broken above its 20-day SMA, signaling a breakout is underway and suggesting selling pressure is exhausting.
Pattern: breaking out / accumulation zone below 200-day SMA
Key Support: $44-45 (critical support)
Resistance Levels:
$60-62 (first target)
$74-78 (previous high target)
$106 (fair value)
RSI: Below 50; neutral to oversold, still has room to run!
Targets:
$60-62 (20-25% upside).
$74-78 (50% upside).
Extreme-high RSI reading greater than 70.
$106 fair value target (114% upside).
What Could Go Wrong with CRSP (Risk Factors)
Biotech Volatility: Can move sharply on clinical data, FDA decisions, and sentiment. Further rotation away from growth could test lower levels.
Pipeline Risk: Disappointing clinical data in immuno-oncology, cardiovascular, or diabetes programs could crater the stock. Biotech is binary.
Casgevy Commercial Risk: Slow uptake, reimbursement challenges, or competition could pressure the stock.
This is where your stop protects you. If price breaks below $43, exit. If it holds above $44, you’ve got room to run.
Nurse in The Market Back-up Picks
Backup Pick #1: Russell 2000 Small Cap ETF (IWM)
Current Price: $251.29
Entry Zone: $248-253
Stop: $237.50
Targets: RSI above 70, previous high $267-270 (6-8% upside)
Leverage Play: URTY (3x leverage; tighter stops required)
Why I Like IWM Here:
Small caps are consolidating after underperforming large caps, creating a mean reversion opportunity.
IWM 0.00%↑ posted +1.56% over 5 days and is holding above $245-250 support.
If the Dow’s breakout signals improving breadth and the Fed signals rate cuts, small caps historically rip higher fast.
This is a bet on market breadth improvement and rotation back into beaten-down small caps.
Backup Pick #2: Real Estate Sector ETF (XLRE)
Current Price: $41.61
Entry Zone: $41-42
Stop: $39.00
Targets:
RSI above 70
Previous high above $43.60 (5% upside)
Leverage Play: DRN DRN 0.00%↑ (3x leverage)
Why I Like It: Real estate XLRE 0.00%↑ is showing relative strength (+3.28% over 5 days) and benefiting from the Bonds TLT 0.00%↑ breakout.
When bonds rally, REITs (like AGNC 0.00%↑ ) benefit from lower borrowing costs, more attractive dividend yields vs. bonds, and higher property valuations.
XLRE is pushing toward $43.60 with clear support at $39.
This is a defensive sector play that benefits from bond strength and rotation into yield-generating assets.
The Teaching Moment with Nurse Jess
What Made These Trades Stand Out
Here’s my exact process for finding CRSP, IWM, and XLRE; I replicate this every week:
Avoid overextended plays: Oil (USO) ripped 11% with an extreme-high RSI reading. Don’t chase momentum when it’s fully extended. Look for quality names in beaten-down sectors.
Scan for massive discounts: CRSP at $49.51 is 53% below fair value of $106. Gene editing pioneer, first approved CRISPR therapy, robust pipeline—all on sale because the market rotated out of biotech. The best trades are the ones nobody is talking about. While everyone chases oil, I’m accumulating quality at fire-sale prices.
Check sector rotation: Bonds (TLT) breaking out signals rate relief. Real estate (XLRE) benefits. Small caps (IWM) consolidating for mean reversion. Position ahead of rotations, don’t chase them after they’ve run.
Confirm technical setups with clear risk: CRSP above $44, IWM above $237.50, XLRE above $39. Clear line in the sand. If support breaks, exit. If it holds, room to run.
Look for multiple ways to win: CRSP works as a buy-and-hold position (fair value $106) AND swing trade (targets $60-62, $74-78). IWM and XLRE give macro diversification. URTY and DRN offer leverage.
Remember: Never chase momentum when it’s fully extended. The best trades have clear entries, defined risk, and multiple ways to win.
Final Thoughts
This is about playing the opposite side of the crowded trade.
Oil (USO) is overextended. Biotech (IBB) is beaten down. Real estate (XLRE) is benefiting from bond strength. Small caps (IWM) are ready for mean reversion.
CRSP is a gene editing pioneer trading at a 53% discount to fair value.
At $49.51, this is a gift for long-term investors and a clean swing setup for traders.
Casgevy is a breakthrough therapy, the pipeline is advancing, and the gene editing revolution is just getting started.
IWM and XLRE offer macro-driven setups with leveraged options (URTY, DRN) for aggressive traders.
Respect your stops. Practice proper position sizing. Biotech is volatile—size accordingly.
Following a systematic approach, thinking contrarily, and staying disciplined compounds over time.
Let me know what you’re watching and thank you so much for reading! 🙌
-Nurse Jess 🤝
📌 Bookmark this post. Track these setups through the week and see how they play out. This is how you develop an edge—by studying real-time trade ideas and learning what works.
Financial Disclaimer: This is not financial advice. All trades carry risk. Biotech stocks are highly volatile and speculative. Always do your own due diligence and consult with a financial advisor before making investment decisions.
let us know what you think about this week's first top trade pick!